Condom-maker Karex to expand sanitiser productio
n
KUALA LUMPUR, June 12 — The world’s biggest condom maker, Karex Bhd, is responding to the Covid-19 pandemic by expanding production of sanitising products.
The company started producing hand sanitisers under the brand HANS in March and is expected to come out with a sanitising spray by the end of this month and wipes before August.
Group chief executive officer Goh Miah Kiat said the company made the shift to address the shortage of sanitisers, considering that it doesn’t require major adjustments to their manufacturing process.
“The thing is, we already have those tanks. We have the mixing tanks, the bottling machines and they were already there,” he told Bernama.
He said the changes made included shifting the production from water-based to alcohol-based as well as conducting the necessary research to come up with a formula that is safe and effective.
Goh said the company had initially stopped producing lubricants to make way for hand sanitiser production to meet local demand, but has now resumed lubricant production.
He said the company’s sanitiser product line does not comprise a major part of its product range but is expected to expand in the future.
“To date, around 100,000 bottles have been produced. The hand sanitisers are currently available for purchase online,” he said.
Karex produces one out of five condoms on the market today, as well as lubricants and sheaths for medical devices.
The company recorded a net loss of RM1.13 million in the third quarter ended March 31, 2020 from a net profit of RM165,000 in the same period last year, despite revenue growing to RM99.15 million in the quarter from RM85.11 million in the third quarter of 2019.
According to a Fior Markets report, demand for hand sanitising products, including spray, gel, wipe and foam, is expected to double to US$2.14 billion (RM9.1 billion) by 2027. —Bernama
Last edit: 4 years 5 months ago by iCann. Reason: update
HOPU PARTNERS WITH SUBSTANTIAL SHAREHOLDERS TO
PRIVATISE PERENNIAL AT S$0.95 PER SHARE
I urged all shareholders not to accept the offer as its way below the 50% discount to the NAV and not taking account of the RNAV that is way above $2+. Moreover, some of the one-hub integrated malls are already commercialising going forward.
HOW CAN THIS LOUSY DEAL FROM MAJOR SHAREHOLDERS CAN BE APPROVED BY OUR INDEPENDENT DIRECTORS.PAID BY US.
Impact Biomedical and GRDG Sciences Announce Medical
Technology Package Valued at USD 1.39 Billion (SGD 1.97
Billion) by Independent Experts
Impact Biomedical’s Majority Owned Next Generation Medical
Technologies Valued at USD 592 Million (SGD 841 Million) by
Independent Experts
PROPOSED US$50 MILLION SHARE SWAP
ENTRY INTO LEGALLY BINDING TERM SHEET
1. Introduction
1.1 The Board of Directors (the “Board”) of Singapore eDevelopment Limited (the “Company” and together with its subsidiaries, the “Group”) wishes to announce that Global BioMedical Pte. Ltd.
(“Global BioMedical”), a wholly-owned direct subsidiary of the Company, and Impact BioMedical, Inc. (“Impact BioMedical”), a wholly-owned direct subsidiary of Global BioMedical, had, on 12
March 2020, entered into a legally binding term sheet (the “Term Sheet”) with Document SecurityNSystems, Inc. (“DSS”) a NYSE listed company and DSS BioHealth Security, Inc. (“DSS BioHealth”)
in relation to, inter alia:
(a) the disposal of 1,000 ordinary shares in the share capital of Impact BioMedical held by Global BioMedical (the “Sale Shares”), representing the entire issued and paid-up share capital of Impact BioMedical, to DSS BioHealth; and
(b) the allotment and issue of 14,500,000 new ordinary shares in the share capital of DSS (the “New DSS Shares”), representing approximately 18.93% of the total issued and paid-up share
capital of DSS on an enlarged basis, to Global BioMedical,
(the “Proposed Share Swap”)
THIS IS ANOTHER LOUSY DEAL FROM MAJOR SHAREHOLDER AND CAN BE APPROVED BY OUR NDEPENDENT DIRECTORS.PAID BY US.
WHY ARE ALL THESE SO-CALLED RESPECTABLE ENTREPRENEURS BULLY THEIR MINORITY SHAREHOLDERS AND WE SIMPLY HAVE NOWHERE TO GET HELP.
frankly, this stock should worth a lot more and up faster during the past few announcements if the medical reports are true. But for ''unknown reasons'', the price was FORCED down for accumulations every time after a press release. now that they have accumulated enough, the price spike in a day that needed to take a year time.
also, the most unbelievable thing is that they ''purposely'' want to share swab with a multi-year loss-making DSS NASDAQ co. for $50m out of which only $4.5m in cash and the rest are in coupons that don't bear interest.
IIRC there is no cash component to the deal, totally a share swap. And DSS is controlled by Chan Heng Fai, the chairman of SeD, so he also has skin in the game after the share swap. What is your opinion?
